Abstract
Summary: Levonorgestrel releasing intrauterine system have excellent contraceptive efficacy with simultaneous lowering of menstruation’s blood loss. It could be used for therapy of endometrial hyperplasia in perimenopause. In position of gestagen part of the hormone replacement therapy it has high control of endometrial proliferation. It is conjoined with the zero increasing of risk of thromboembolic disease in combination with transdermal oestrogen’s application. Key words: menopause – hormone replacement therapy – levonorgestrel releasing intrauterine system – thromboembolic disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have